EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real‐world incidence and risk factors of level 3 (severe) hypoglycaemia in adults with type 1 or 2 diabetes ( iNPHORM , United States)

Alexandria Ratzki-Leewing iD, Jason E Black, Jasminder Bhatti, Bridget L Ryan, Guangyong Zou, Yu Kuei Lin iD, Shuo J Huang, Rozalina G McCoy, Stewart B Harris

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Alexandria Ratzki-Leewing und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Maryland Institute for Health Computing, North Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Hypoglycemia, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi Global, Montgomery County, Maryland and The University of Maryland Strategic Partnership: MPowering the State, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Level 3 (severe) hypoglycaemia is a serious, yet preventable, complication of insulin‐ or secretagogue‐treated diabetes. However, real‐world insight into its incidence and risk factors remains limited. We analysed data from the iNPHORM study to address this gap. Materials and Methods iNPHORM is a prospective internet panel survey of US adults (aged 18–90) with type 1 diabetes (T1D) or insulin‐ and/or secretagogue‐treated type 2 diabetes (T2D). A screener, baseline and 12‐monthly follow‐up questionnaires captured data on Level 3 hypoglycaemia and participant characteristics. Crude incidence proportions and annualized event rates were calculated. Repeated LASSO selection and negative binomial regression identified risk factors, with separate models for T1D and T2D.

Results

Among 985 participants (T1D: 16.7%), 35.0% experienced ≥1 Level 3 event over follow‐up (T1D: 45.0%; T2D: 33.0%). The annualized rate was 4.98 EPPY (T1D: 3.56; T2D: 5.26). In T1D, rates were higher among individuals identifying as non‐White (RR [rate ratio]: 2.03), with prior diabetes ketoacidosis (RR: 6.49), and greater fear of hypoglycaemia (RR: 1.41). Prior diabetes education (RR: 0.42) was protective. In T2D, rates were higher with younger age (RR: 0.77 per 10‐year increase), greater fear of hypoglycaemia (RR: 1.18), more diabetes complications, higher secretagogue dose, more diabetes visits (RR: 1.72), longer use of continuous/flash glucose monitoring, impaired awareness of hypoglycaemia and a greater number of past healthcare‐requiring severe hypoglycaemia (RR: 1.12).

Conclusions

Level 3 hypoglycaemia remains common in T1D and T2D. Findings support risk‐targeted prevention and diabetes care strategies that co‐prioritize safety and effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypoglycemiaDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Hypoglycemic AgentsHumansMaleFemaleMiddle AgedAdultIncidenceRisk FactorsUnited StatesAgedYoung AdultAdolescentProspective StudiesAged, 80 and overInsulinSeverity of Illness Index

Stichwörter der Autor:innen

hypoglycaemiainsulininsulin secretagoguespharmacoepidemiologytype 1 diabetes mellitustype 2 diabetes mellitus

Substanzen

Hypoglycemic AgentsInsulin

Autor:innen und Institutionen

  • University of Maryland Institute for Health Computing, North Bethesda, Maryland, USA.
  • Division of Gerontology, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western Centre for Public Health and Family Medicine, Western University, London, Ontario, Canada.
  • Department of Family Medicine, Schulich School of Medicine & Dentistry, Western Centre for Public Health and Family Medicine, Western University, London, Ontario, Canada.
  • Robarts Research Institute, Western University, London, Ontario, Canada.
  • Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.

ORCID-Profile: Alexandria Ratzki-Leewing, Yu Kuei Lin

Förderung

  • Sanofi Global
  • Montgomery County, Maryland and The University of Maryland Strategic Partnership: MPowering the State
  • NIDDK NIH HHS
  • Montgomery County Government
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Ratzki-Leewing, A., Black, J. E., Bhatti, J., Ryan, B. L., Zou, G., Lin, Y. K., Huang, S. J., McCoy, R. G., & Harris, S. B. (2026). Real‐world incidence and risk factors of level 3 (severe) hypoglycaemia in adults with type 1 or 2 diabetes ( iNPHORM , United States). Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70252

Vancouver

Ratzki-Leewing A, Black JE, Bhatti J, Ryan BL, Zou G, Lin YK, et al. Real‐world incidence and risk factors of level 3 (severe) hypoglycaemia in adults with type 1 or 2 diabetes ( iNPHORM , United States). Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70252

BibTeX
@article{RatzkiLeewing2026,
  author = {Ratzki-Leewing, Alexandria and Black, Jason E and Bhatti, Jasminder and Ryan, Bridget L and Zou, Guangyong and Lin, Yu Kuei and Huang, Shuo J and McCoy, Rozalina G and Harris, Stewart B},
  title = {Real‐world incidence and risk factors of level 3 (severe) hypoglycaemia in adults with type 1 or 2 diabetes ( iNPHORM , United States)},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70252}
}
Kostenlos starten →